Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 2/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.36 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5137318 | 0.90 | PIN1 (0.36) | PLA2G4APIN1HDAC1HDAC6 | |
| SCHEMBL5136239 | 0.84 | L3MBTL1 (0.34) | HDAC1HDAC6 | |
| SCHEMBL648619 | 0.83 | AGTR1 (0.40) | AGTR1AGTR2PLA2G4APIN1 | |
| SCHEMBL5135849 | 0.83 | MDM2 (0.36) | PLA2G4APIN1HDAC1HDAC6 | |
| SCHEMBL5136020 | 0.82 | PTGER4 (0.41) | PLA2G4APIN1HDAC1 | |
| SCHEMBL5072300 | 0.79 | PTGER4 (0.36) | HDAC1HDAC6 | |
| SCHEMBL5137484 | 0.77 | PTGER4 (0.34) | PLA2G4APIN1 | |
| SCHEMBL5135987 | 0.77 | TP53 (0.37) | — | |
| SCHEMBL1913031 | 0.76 | TSHR (0.40) | — | |
| SCHEMBL1912873 | 0.74 | CRHR1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |